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Abstract
INTRODUCTION: There is growing interest in using positron emission tomography (PET) standardized uptake
values (SUVs) to assess tumor response to therapy. However, many error sources compromise the ability to detect
SUV changes. We explore relationships between these errors and overall SUV variability. METHODS: We used
simulations in a virtual clinical trial framework to study impacts of error sources from scanning and analysis effects
on assessment of SUV changes. We varied tumor diameter, scan duration, pretherapy SUV, magnitude of change
in SUV, image reconstruction filter, and SUV metric. Poisson noise was added to the raw data before image
reconstruction. Variance from global sources of error, e.g., scanner calibration, was incorporated. Two thousand
independent noisy sinograms per scenario were generated and reconstructed. We used SUVs to create receiver
operating characteristic (ROC) curves to quantify ability to assess response. Integrating area under the ROC curve
summarized ability to detect SUV changes. RESULTS: Scan duration and image reconstruction method had
relatively little impact on ability to measure response. SUVMAX is nearly as effective as SUVMEAN, especially with
increased image smoothing and despite size-matched region of interest placement. For an effective variability of
15%, we found the Positron Emission Tomography Response Criteria in Solid Tumors criteria for measuring
response (±30%) similar to the European Organization for Research and Treatment of Cancer criteria (±25%).
CONCLUSIONS: For typical PET variance levels, tumor response must be 30% to 40% to be reliably determined
using SUVs. PET scan duration and image reconstruction method had relatively little effect.
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Introduction
Increasingly, 18F-fluorodeoxyglucose positron emission tomography
(FDG-PET) imaging is being used to assess response to cancer
therapy or for disease progression (e.g., [1,2]). A typical example is
shown in Figure 1, which illustrates the changes in FDG uptake that
can occur over the period of several months.
Quantitative positron emission tomography/computed tomography
(PET/CT) is a valuable tool for assessment of an individual’s response
to therapy and for clinical trials of novel cancer therapies because it can
measure metabolic changes, which are a better indicator of response
than anatomic size changes [3]. Success with this approach has been
demonstrated using the glucose analog FDG for evaluation of therapy-
induced changes in metabolic activity in several studies, including lung
cancer [4] and gastrointestinal tumors [5]. Thus, quantitative PET im-
aging has an enormous potential to boost the efficiency of evaluating
clinical trials of new therapies [6]. Changes in tumor standardized up-
take values (SUVs) can be used to assess drug efficacy in clinical trials
and to assess response to therapy for individual patients or monitor
disease progression.
Two sets of criteria have been proposed to classify changes in
measured FDG uptake as response to therapy or disease progression.
These are the European Organization for Research and Treatment of
Cancer (EORTC) [7] and Positron Emission Tomography Response
Address all correspondence to: Robert L. Harrison, MA, Box 357987, Department of
Radiology, University of Washington Medical Center, Seattle, WA 98119. E-mail:
roberth@uw.edu
1This workwas supported in part byNational Institutes ofHealth grantsRO1-CA042593,
RO1-CA126593, and UO1-CA148131.
Received 15 December 2013; Revised 10 March 2014; Accepted 11 March 2014
Copyright © 2014 Neoplasia Press, Inc. All rights reserved 1944-7124/14/$25.00
DOI 10.1593/tlo.13847
www.transonc.com
Trans la t iona l Onco logy Volume 7 Number 1 February 2014 pp. 138–146 138
Criteria in Solid Tumors (PERCIST) [8] criteria, which are summa-
rized in Table 1.
Unfortunately, there are several contaminants in PET data that
limit the precision of SUV measurements. There have been several
single- and multi-center studies that have sought to quantify the
short-term (i.e., no change in tumor status) test-retest repeatability
of SUV measurements [9–16]. The goal of these studies is, in gen-
eral, to determine the overall measurement SUV variability, which
then allows estimating the probability that a measured change in
SUV is due to chance. These studies typically find a test-retest varia-
bility of 10% to 12%, which includes all possible short-term effects,
under the assumption of no change in tumor status. There are several
sources of error, as illustrated in Figure 2, including instability in
tomograph calibrations, imperfect scatter and detector response cor-
rections, the errors in CT-based attenuation correction, variability
of dose calibrators, inconsistent imaging protocols, variations in
PET image reconstruction and analysis, and the underlying biologic
variability [10,11,16–22].
While some effort has gone into understanding these sources of
variance individually and in aggregate, there are few if any studies
that try to determine the relative importance of factors that affect
the overall test accuracy. Knowledge of the impact of these factors
can lead to more efficient imaging methods that allow an earlier
assessment of response to therapy and can provide a better under-
standing of the bias and variability of the current FDG-PET imaging
methods used to assess response to cancer therapy and/or monitor
disease progression. We conceptually divide the sources of variance
into several groups as shown in Figure 2.
1. Underlying biologic variability of tumor uptake of FDG.
2. Variability of tumor uptake of FDG due to variations in
patient preparation, injection timing, and other effects.
3. Variability caused by changes in the data acquisition, including
scan duration and differences in sensitivity between scanners.
4. Variability caused by calibration variations in the PET scanner
and/or dose calibrator.
5. Variability due to changes in data processing (e.g., scatter
correction) and image reconstruction method.
6. Variability due to the choice of metric [e.g., mean SUV versus
maximum SUV in a region of interest (ROI)].
This study uses a virtual clinical trial framework for simulation
studies that include a model of the PET acquisition physics to evaluate
the relative importance of scan duration, data processing, calibration
effects, and analysis method on the ability to reliably detect change
in longitudinal SUV measurements. In other words, we evaluate the
impact of the sources of variability (items 3-6 above) in the sense of
testing what an imaging system could measure, independent of the
patient and/or pathobiology. Using simulations, we create multiple
independent, identically distributed (i.i.d.) realizations of pre-therapy
and post-therapy images of a breast tumor with and without change
to create receiver operating characteristic (ROC) curves for the prob-
ability of making a correct decision for different combinations of the
acquisition, processing, and analysis parameters.
Materials and Methods
We used our PET analytic simulation package (ASIM) [23] to simu-
late PET imaging of FDG uptake by a breast cancer tumor pre-therapy
and post-therapy (Figure 4). This was followed by PET image recon-
struction using the Software for Tomographic Image Reconstruction
library, an open source package of image reconstructions for PET data.
The overall flow is illustrated in Figure 3. We provide more details on
each section in turn. A summary of the parameters varied, values used,
and number of combinations is given in Table 2.
Tumor Model
As a model for the tumor and FDG uptake, we used an approxi-
mately anthropomorphic test object (Figure 4) specified as a collection
of truncated ellipsoids. On the basis of clinical experience, we assumed
a background tissue SUV of 0.5, a lesion diameter of either 15 or
Figure 1. FDG-PET/CT images of a lung tumor (arrow) over a
period of several months, in this case showing disease progres-
sion with increased PET SUVs, even though there is no substantial
increase in lesion size as seen on CT.
Table 1. Change in Tumor SUV and Classification of Response for EORTC and PERCIST Criteria.
Classification of Response EORTC Criteria PERCIST Criteria
CMR: Complete metabolic response FDG uptake in tumor indistinguishable from surrounding normal tissue Same as EORTC
PMR: Partial metabolic response Decrease in SUV of more than 25% Decrease in SUVlbm of more than 30%
SMD: Stable metabolic disease Increase in SUV of less than 25% or decrease of less than 25% Not CMR, PMR, or PMD
PMD: Progressive metabolic disease Increase in SUV of more than 25% Increase in SUVlbm of more than 30%
Notes: 1) These are a simplified subset of the full criteria, which also include size changes, therapy status, and so on. 2) The PERCIST criteria use lean body mass normalized SUVs (SUVlbm).
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30 mm, pre-therapy SUVs of 1, 2, or 4, and post-therapy changes of
0%, ±10%, 20%, 30%, and 40%. The attenuation map assumed that
the object was composed of soft tissue, lung, and bone.
Noise Model
There are several sources of variability that are considered. These
include the following:
1. The underlying biologic metabolic variability.
2. The variability of tracer uptake with patient preparation, which
is affected by plasma glucose levels and the duration between
injection and scan start.
3. Operator errors in measurement of activity and/or time of
measurement and errors in data entry. Kinahan and Fletcher
[24] show that there are 15 to 19 “data steps” per patient scan.
In comparing two patient scans, the number of steps increases
up to 30 to 38.
4. The scan protocol variability, largely determined by the choice
of scanner (through the scanner’s impact on the noise equiv-
alent count rate [25]), but also a function of injected activity,
the acquisitionmode [i.e., the so-called two-dimensional (2D) or
3D mode [26]], the direction of scan (head to toe or vice versa),
and scan duration.
5. The scanner calibration variability, which has been shown
to range from less than 3% in the short term [27] to 4% to
5% over a period of one month for a carefully calibrated
scanner [28]. If errors occur during calibration, the variabil-
ity can be significantly greater, from 10% [28] to 40% or
more [29–31].
6. The variability due to image processing, which includes cor-
rections for scattered coincidences (typically not user selectable),
choice of image reconstruction algorithm, and reconstruc-
tion parameters.
7. Variations due to the image analysis metric used, the software
used for estimating metric values, and reader variability.
Many of the above sources of variation are not known, although,
as discussed above, studies of instrumentation and operator factors
have shown variations of 10% to 40% or more. Since many of the
sources of variability are global (e.g., scanner calibration, plasma
glucose levels, residual dose information, timing errors, and so on)
we assumed a first-order additive and noncorrelated noise model of
the following form:
σ2E = σ
2
B + σ
2
A; ð1Þ
where σE
2 is the effective overall global variability, σB
2 is the under-
lying biologic noise, and σA
2 is the additional additive noncorrelated
global variability. For this study, we assume biologic noise to be
around 10%, basing this on comparison of patient test-retest variabil-
ity, around 10% to 12% (as discussed in the Introduction), with
similar phantom test-retest variability, around 3% (item 5 above).
If we then assume a range of 0% to 15% for additional additive
global variability, the effective overall noise values range from 10%
to 18%. For completeness, we modeled an effective overall global
variability ranging from 0% to 20% in steps of 5%.
Imaging Physics Simulation
The PET analytic simulation package (ASIM) [23,32], an open
source projection-based analytic simulation package, takes as an in-
put a collection of truncated ellipsoids (e.g., Figure 4) and calculates
noise-, random-, and scatter-free raw sinogram data with realistic
resolution properties. Estimated random and scatter distributions
are then added to the sinograms before statistical noise (Poisson)
is applied.
For this study, we simulated three different coincident photon
count levels corresponding to different scan durations, which we
designated as a normal scan duration, a 1/4 scan duration, and a
1/16 scan duration. To estimate typical count levels, we reviewed
the most recent eight PET/CT scans acquired at our facility. Our
protocol is typical of many PET imaging centers: Patients are in-
jected with 370 MBq (10 mCi) of FDG, followed by a 60-minute
uptake period, and then imaged for 5 minutes per bed position
in 3D mode. The average total counts in the patient studies was
2.7 ± 0.7 million counts per image plane (true + scattered + random
coincidences). For the simulations, the ratio of true/scattered/random
Figure 2. A model of the data flow and factors affecting bias and precision of PET SUVs (modified from [23]).
Figure 3. Overview of the data flow and parameters for this study.
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coincident events was set to 1:0.35:1, and in the normal scan duration,
there were 1.2 million true events, 0.42 million scattered events,
1.2 million random events, or roughly 2.8 million total events per
image plane, close to the measured values for typical clinical scans.
The simulations used as a scanner model a three-ring subset of the
ECAT HR+ tomograph [33]. Because the ASIM simulation is focused
on reproducing the noise and resolution properties of the projection
data rather than simulating the hardware and physical processes, the
results are intended to be reflective of any tomograph with similar
resolution and noise equivalent count characteristics.
For each tumor model setting and scan duration, 2000 i.i.d. real-
izations of the sinograms were generated. The choice of 2000 i.i.d.
realizations was based on the ability to directly calculate the ROC
curves, as shown below, instead of relying on estimation using
parametric fitting.
Image Reconstruction
Images were reconstructed from the noisy sinograms using the
Software for Tomographic Image Reconstruction library, an open
source package of image reconstruction algorithms for PET data
[34]. The data were reconstructed using ordered subset maximum
a posteriori one-step late (OSMAPOSL) or filtered backprojection
(FBP) filtered to achieve final image resolutions, measured from
images of an off-center point source in a warm background, of either
5 or 7.5 mm (which we refer to as high and low resolutions, respec-
tively) full-width at half-maximum. The OSMAPOSL image recon-
struction used two iterations of 12 subsets and inter-iteration filtering
[35,36] and is comparable to OSEM reconstructions post-filtered to
a similar resolution. The OSMAPOSL and FBP resolutions were
carefully matched by adjusting the OSMAPOSL inter-iteration fil-
tering to match the FBP resolution. The reconstructed data were
corrected for attenuation and random and scattered coincidences
using the mean estimates as inputs to the image reconstruction.
Image Analysis
The SUVs were measured using size- and location-matched
spherical ROIs over the tumors (diameters of either 15 or 30 mm).
For each image, the mean SUV in the ROI (SUVMEAN) and the
maximum SUV within the ROI (SUVMAX) were recorded. We then
added additional noise to these SUV measurements to represent the
biologic variability and variability from scanner and/or dose calibra-
tion discussed above. The additional noise was modeled as a normal
function with mean of 0 and SD of 0%, 5%, 10%, 15%, or 20% of
the tumor SUV.
Nonparametric ROC analysis was used to quantify the ability to
detect response or progression. First histograms of the pre-therapy
and post-therapy SUV measures were formed from the 2000 realiza-
tions. Then, an SUV cutoff threshold for classification was set and
the fractions of the resulting true-positive and false-negative cases
were counted. This was repeated over the range of SUVs to generate
an ROC curve [37]. For each ROC curve, the area under the curve
(AUC) was calculated as the overall figure of merit.
Due to the large number of ROC curves and AUC values pro-
duced (Table 2), we use one set of simulation parameters as a base
case and vary each of the other parameters as an excursion from this
set (Table 3).
Results
Measurement Process
Samples of images for the 30-mm tumor with SUV = 2 for
each scan duration and reconstruction filter are shown in Figure 5.
Figure 6 shows a histogram of the pre-therapy and post-therapy
SUVs for n = 2000 cases used to create the ROC curves for the
reference case (Table 3). ROC curves are created by moving a thresh-
old along the x-axis SUVs and, for each value, calculating the true-
positive fraction as the fraction of pre-therapy SUVs greater than
the threshold and the false-positive fraction as the fraction of post-
therapy SUVs greater than the threshold. An ROC curve gives a
summary view of how well a threshold can differentiate pre-therapy
and post-therapy cases (i.e., determine if there has been a change) for
a given set of conditions.
Scan Duration and Calibration/Protocol Noise
In Figure 7, we show a family of ROC curves for SUVMEAN,
three different scan durations, and with 0% and 15% added calibra-
tion noise. The other simulation parameters are those given for the
reference simulation case (Table 2). We note that in the absence of
calibration noise, even with 1/16 of the normal scan duration we can
Table 2. Summary of Study Parameters.
Parameter: Values Used Number and Type of Data Sets
Breast tumor diameter: 15 or 30 mm 2 noise-free sinograms
Pre-therapy SUV: 1, 2, or 4 (background = 0.5) × 3 = 6 noise-free sinograms
Tumor response/progression: 0% and ±10%,
20%, 30%, 40%
+ × 9 = 54 noise-free sinograms
Scan duration: normal, 1/4, 1/16 time × 3 = 162 noisy sinograms
Noise realizations per simulation: 2000 × 2000 = 324K noisy sinograms
Reconstruction algorithms: OSMAPOSL or FBP × 2 = 648K images
Smoothing: image resolution of 5 mm or 7.5 mm × 2 = 1296K images
Metric: SUVMEAN or SUVMAX × 2 = 2.6 million
Calibration noise: 0%, 5%, 10%, 15%, 20% × 5 = 13 million measurements
Resulting ROC curves and AUC values 5760 values
Figure 4. Tumor model and input object.
Table 3. Simulation Parameters for Reference Case.
Parameter Value
Breast tumor diameter 30 mm
Pre-therapy SUV 2
Post-therapy tumor response −30% (SUV = 1.4)
Scan duration 1/4 normal
OSMAPOSL filter resolution 5 mm
Calibration/protocol noise 15%
Metric SUVMEAN
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distinguish the response to therapy almost perfectly. The normal scan
duration with no calibration noise curve was omitted as it lies almost
directly on the ideal curve, as does the 1/4 duration in this case.
When 15% calibration noise is added, however, the ROC curves
shift from the ideal response. The difference between a normal du-
ration scan and 1/4 normal duration scan is small. Reducing the du-
ration to 1/16 leads to a more substantial decrease in performance.
By plotting the AUC as function of parameters, a larger dimension
of parameters can be evaluated. As shown in Figure 8, decreasing the
scan duration leads to lower AUCs. However, the effect of increased
added noise is much greater over the range of values considered. The
one exception is for the shortest scan duration (1/16 normal) in com-
bination with SUVMAX, where performance is essentially random.
Tumor Size and Filter Resolution
Figure 9 shows the ROC curves for variations in the tumor size
and filter resolution; Table 4 summarizes the corresponding AUCs.
The tumor size has a small but measurable effect on the SUVMEAN
but no noticeable effect on SUVMAX. The opposite is true for the
filter resolution: It has almost no effect on the SUVMEAN measure-
ment but a striking effect on SUVMAX, with the lower resolution fil-
ter giving much better results. Indeed, SUVMAX essentially matches
SUVMEAN when using the low-resolution filter.
Sensitivity to Pre-Therapy SUV and Change in SUV
Figure 10 shows the ROC curves for each post-therapy percentage
response for a pre-therapy SUV of 2. Table 5 summarizes the AUCS
Figure 5. Typical reconstructed images for the 30-mm tumor with
SUV = 2. Note that the 5-mm 1/4 duration scan corresponds to the
reference case in Table 3.
Figure 6. Histograms of the pre-therapy and post-therapy SUVMEAN
from the 2000 realizations for the reference case simulation.
Figure 7. ROC curves showing the ability of SUVMEAN analysis to
detect tumor response as a function of scan duration and added
noise. The curves for normal and 1/4 scan duration with 0% added
calibration noise are omitted as they as indistinguishable from the
edges of the graph.
Figure 8. Summary of AUC values for all scan durations, all
levels of calibration noise, and both metrics, using reference
case parameters.
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for the curves in Figure 10 as well as for the other pre-therapy SUVs
and for both post-therapy tumor progression and response.
Under the assumption of 15% effective noise, the AUC approaches
1 for SUVMEAN and SUVMAX for a true tumor decrease of 40% (and
for the case of pre-therapy tumor SUV of 4 for SUVMAX).
In the typical scenario of a single measurement of SUV pre-
therapy and post-therapy, the question of interest is the probability
of the measured change in SUV representing a true change in tumor
status. This is analyzed in Tables 6–8, which presents the probability
of a fixed a priori threshold for changes in SUV determining tumor
change as a function of the true change. For example, in Table 6, we
see in the −40% column that 81% of tumors with −40% treatment
response are correctly categorized as partial metabolic response (PMR)
by the EORTCcriteria; however, in the −20% column, we see that 37%
of tumors with −20% treatment response are incorrectly categorized
as PMR by the EORTC criteria. The thresholds used in this analysis
are those defined in the EORTC and PERCIST criteria to determine
PMR, stable metabolic disease (SMD), or progressive metabolic disease
(PMD; Table 1).
The results in Tables 6 to 8 indicate that the EORTC criteria
have a higher sensitivity but a lower specificity than the PERCIST
criteria for determining PMR and PMD and lower sensitivity and
higher specificity for determining SMD. There is an asymmetry seen
between the response of tumors with positive and negative changes in
SUV. For instance, in Table 7, 19% of tumors with a −40% change
in SUV meet the EORTC criteria for SMD, while 29% of the
tumors with a +40% change in SUV meet the criteria. This asym-
metry is caused by the way we model the measurement error shown
in Equation 1: The variance for the measured SUV is calculated as a
percentage of the true tumor SUV; thus, the absolute variance in the
Figure 9. (A) ROC curves showing the ability of SUVMEAN and
SUVMAX to detect tumor response for both tumor sizes and image
reconstruction filter resolutions. (B) Enlargement of upper left
quadrant of A.
Table 4. AUCs for Different Tumor Sizes and Reconstruction Filters.
Filter Tumor Size (Diameter)
15 mm 30 mm
SUVMEAN SUVMAX SUVMEAN SUVMAX
5 mm 0.90 0.87 0.94 0.87
7.5 mm 0.91 0.92 0.94 0.93
Figure 10. ROC curves showing the ability of SUVMEAN and SUVMAX
to detect tumor response for pre-therapy SUV of 2 and for all
response levels tested.
Table 5. AUC as a Function of SUV Metric (SUVMEAN or SUVMAX), Pre-Therapy SUV, and the
Change in SUV (ΔSUV), which Represents the Post-Therapy Progression or Response.
ΔSUV Pre-Therapy SUV
SUVMEAN SUVMAX
1 2 4 1 2 4
+40% 0.91 0.93 0.93 0.85 0.88 0.89
+30% 0.86 0.88 0.88 0.78 0.82 0.84
+20% 0.77 0.79 0.80 0.70 0.75 0.75
+10% 0.65 0.66 0.68 0.62 0.63 0.65
−10% 0.67 0.67 0.69 0.62 0.62 0.64
−20% 0.80 0.83 0.83 0.73 0.75 0.80
−30% 0.91 0.94 0.94 0.82 0.87 0.89
−40% 0.97 0.98 0.99 0.89 0.94 0.96
The AUCs shown for positive ΔSUV are for measuring progression, and the AUCs shown for
negative ΔSUV are for measuring response.
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measured SUV is greater for tumors with positive changes than those
with negative changes.
Discussion
Because clinical trials are expensive and time-consuming, several
groups are researching strategies for trial optimization based on simu-
lation studies [38]. This approach uses computationally intensive
stochastic simulations to optimize experimental design. The goal is
to evaluate probable real-world performance of the trial strategies,
reducing the number of physical trials needed. This approach is also
being extended to studies of clinical trails using medical imaging,
including the very computationally intensive task of stochastic imaging
simulations [31,39,40]. For example, in the current study, we simu-
lated and analyzed 2.6 million tomographic image sets. We believe
that such studies will lead to task- and patient-specific optimization
of clinical trials that use FDG-PET imaging. To achieve this goal,
task-based strategies for evaluating key parameters, including estimates
of uncertainty, are needed.
We used the framework of a virtual trial to study, independently
of patients and/or pathobiology, the relative importance of the major
sources of variability in measuring a change in FDG-PET SUV. Our
study led to several observations about the effects of these sources of
variability on what an imaging system can measure.
First is that scan duration has a relatively small impact on the abil-
ity to determine if there was a change in SUV for a primary tumor
(Figures 7 and 8), particularly if using SUVMEAN. This does not
imply, however, that scan duration can be reduced without penalty.
For example, on the basis of the well-known connection between
scan duration and lesion detection, if a longer scan leads to the
detection of a low conspicuity and previously unknown secondary
tumor, it can lead to a major change in patient status and manage-
ment. However, for the primary task of determining if there has been
a change in SUV for known lesions, our data show that a large
reduction in scan time, by a factor of 1/4, causes a noticeable but
small decline in ability to determine a change in SUV even when
using SUVMAX. This suggests that a smaller, 10% to 50%, change
in scan time would not appreciably affect the ability to determine a
change in SUV.
We also evaluated the effect of reconstruction algorithm and
smoothing parameters. While the level of smoothing had a measurable
effect, as discussed below, the choice of the OSMAPOSL or FBP
reconstruction algorithm had little impact (data not shown).
The superiority of SUVMEAN over SUVMAX for matched size
ROIs, as shown in Tables 4 and 5, has been found in other studies
[14], though it has also been shown that this advantage disappears
when variations in defining the ROI are taken into account [11].
We did not include the effect of variations in ROI definition, given
the difficulty in modeling this variability. However, the mechanisms
used in this study can be readily extended to include this effect if
ROI variability models are developed.
Perhaps less well known are that 1) lower resolution reconstruc-
tions can be superior for tasks like detecting tumor response, especially
when using SUVMAX, and 2) SUVMAX is essentially equivalent to
SUVMEAN for low-resolution reconstructions, as can be seen by the
higher AUCs and the ROC curves for the lower resolution filters in
Table 4 and Figure 9. The filtering is reducing the noise in the signal
and essentially making SUVMAX more like SUVMEAN by averaging
over more of the tumor volume. We have also seen this effect with
phantom measurements [27] but without the large number of realiza-
tions and range of parameters. This suggests that SUVMAX from a
highly smoothed image may be quite similar to SUVPEAK (the mean
of voxel values within a sphere of fixed size, with the sphere positioned
within the volume of interest to maximize this mean). The optimal
level of filtering, however, would likely depend on several factors,
including tumor size and tumor-to-background ratio. SUVPEAK (which
was not included in this study) may capture many of the advantages
of SUVMAX without the need for more smoothing. We note also that
if SUVMAX is used as a metric then the tumor sizes used in this study
had essentially no effect on the AUC (Table 4).
An open question in using PET to assess response to therapy is
the choice of appropriate thresholds. The 1999 EORTC criteria have
proposed a definition of PMR (or, respectively, PMD) as a reduction
(increase) in SUV of 25% or more after more than one cycle of
chemotherapy [7]. The more recent PERCIST criteria [8] proposed
thresholds of 30% (with lean body mass normalization) instead. The
results shown in Tables 6 to 8 show that the two criteria are quite
similar, in agreement with recent results reported by Skougaard et al.
[41]: They reported a study of 61 patients with 203 PET scans. Eighty-
seven percent of the patients had the same classification for both
criteria, and the overall survival curves were comparable. For PMR
and PMD, we found that the EORTC criteria have a somewhat higher
sensitivity but a lower specificity (Tables 6 and 8); for SMD (Table 7),
we see the opposite of this, the EORTC criteria have a lower sensitivity
but a higher specificity. The differences between the thresholds for
Table 6. Probability of a Measured Change in SUV Leading to the Classification of PMR (Table 1) as a Function of the True Change in SUV for the EORTC and PERCIST Criteria.
Threshold for Minimum SUV Decrease for PMR True SUV Change
−40% −30% −20% −10% 0% +10% +20% +30% +40%
−25% (EORTC) 81% 58% 37% 20% 11% 5.0% 2.4% 1.5% 0.6%
−30% (PERCIST) 71% 46% 27% 13% 6% 2.4% 1.0% 0.8% 0.4%
Table 7. Probability of a Measured Change in SUV Leading to the Classification of SMD (Table 1) as a Function of the True Change in SUV for the EORTC and PERCIST Criteria.
Range for ΔSUV for SMD True SUV Change
−40% −30% −20% −10% 0% +10% +20% +30% +40%
−25% ≤ ΔSUV ≤ 25% (EORTC) 19% 40% 60% 73% 74% 67% 56% 44% 33%
−30% ≤ ΔSUV ≤ 30% (PERCIST) 29% 53% 71% 82% 82% 75% 64% 52% 39%
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the two criteria may not lead to a substantial difference in clinical trials.
For patient management, however, such criteria would be specific
to the task at hand, taking into account the therapies available and
the relative risk to the patient of being misclassified into each of the
response categories. To determine the overall impact of the PET mea-
surement errors relative to response criteria in a clinical trial, an a priori
distribution of true pre-therapy and post-therapy SUVs for a patient
population would be needed. Such an analysis, however, was not the
intent of this study. The pre-therapy SUVs we simulated do not range
as high as those seen in the clinic nor do the percent responses. How-
ever, we focused our study on low-SUV tumors with partial response
as these are most challenging for response measurement [42].
It is notable, though not surprising, that with the clinically plausible
effective noise level of 15% it can be difficult to correctly determine
response/progression levels of less than 25% to 30%; for instance,
Table 6 shows that with EORTC (or, respectively, PERSIST) a tumor
that has no change in actual SUV has an 11% (6%) chance of being
misclassified as PMR. This emphasizes the importance of controlling
sources of noise, especially in clinical trials [31].
There were several limitations in this study. First, we did not simu-
late spatial heterogeneity in the tumor or background. Second, the
task of simply answering the question “was there a decrease in tumor
uptake?” does not include other relevant tasks, such as lesion localiza-
tion or shape characterization, as well as the detection of new tumors.
Third, we did not include the effects of variation of ROI boundary
localization or alternate image metrics such as SUVPEAK. Fourth, we
did not model the variations due to some of the biologic or scan
preparation variations, such as the duration between FDG injection
and scan start, which affects tumor/background ratios as well as tumor
SUV. In particular, variations in the duration between FDG injec-
tion and scan start cause changes not only in tumor uptake but also
in tumor-to-background ratios. Finally, there are several potential
technical factors, such as patient habitus, nonspherical tumors, time-
of-flight PET imaging, and iterative image reconstruction algorithms
that model detector response that can alter the quantitative nature of
PET imaging. These additional effects could be included in more
detailed models of the PET imaging process.
Finally, we note that we used ASIM because of the ability to com-
pute multiple realizations and the speed with which one can do multi-
ple realizations: It would have been impossible to use a (potentially
more accurate) photon-tracking simulation to create the 288,000 rea-
lizations used in this study, and we have previously shown that ASIM
can capture essential sinogram data quality characteristics [43]. With
ASIM, the major time bottleneck was image reconstruction rather
than simulation.
Conclusions
In this preliminary simulation study, several conclusions can be drawn
about the relative impact of different factors in the ability to detect
response to therapy with quantitative PET imaging:
1. Scan duration and type of image reconstruction algorithm
have relatively little impact on measurement of response.
2. SUVMAX is nearly as effective as SUVMEAN, especially if image
smoothing is increased.
3. For an overall effective variability of 15%, the PERCIST criteria
threshold of a 30% decrease (or, respectively, increase) in SUV
to assert PMR (PMD) will have a lower sensitivity but a higher
specificity for determining PMR than the EORTC criteria
thresholds of 25%.
The current study has several limitations as described above. In
addition, the conclusions should be verified with phantom and patient
studies where feasible. Nevertheless, the effects that are modeled in
this study represent a step toward a fuller understanding of the ability
to measure response to therapy in quantitative PET imaging and the
importance of both characterizing and reducing sources of variability.
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